Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others. The company was founded in 2007 and is headquartered in Lexington, Massachusetts.

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced the Company will release its third quarter 2021 financial results before market open on Tuesday, Nov. 9, 2021.

Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021

Dicerna Pharmaceuticals (DRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Dicerna Pharmaceuticals (DRNA) to Report a Decline in Earnings: What to Look Out for

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) has announced top-line results from its PHYOX4 study of nedosiran for primary hyperoxaluria type 3 (PH3).  Related:   Why Is Dicerna Stock Getting Slammed Today?

Dicerna Posts Mixed Nedosiran Data In Rare Kidney Disease Trial

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced top-line results from its PHYOX4 study designed to evaluate the safety and tolerability of a single subcutaneous dose of nedosiran.

Dicerna Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced an abstract on clinical data from the PHYOX™2 trial of nedosiran has been accepted as a late-breaker poster presentation at ASN.

Dicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that two abstracts related to the Company's clinical development programs have been accepted for poster presentations at AASLD.

Dicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 in November

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options for one new employee

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that it dosed the first subjects in its Phase 1 clinical trial to assess DCR-AUD.

Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today announced new executive leadership appointments.

Dicerna Announces New Executive Leadership Appointments

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the 16th Annual Citi Biopharma Conference on Sept. 9, 2021 at 7:55 a.m. ET. An audio webcast of the fireside chat will be accessible from the “Events and Presentat

Dicerna to Participate in 16th Annual Citi Biopharma Conference

A few weeks ago, DRNA stock tanked after poor PH2 data from its PHYOX trial. The company plans to change strategy and focus on R&D.

Dicerna's PH2 Failure Changes Everything

BioNTech SE

United Continental Hlds

Workhorse Group

Livent Corp

Southwest Airlines

Unity Software

Weightwatchers International Inc.

With the trading day almost halfway over, the S&P 500 and Dow Jones industrial average hit even more record highs in Wednesday's session.

Wednesday Afternoon Analyst Upgrades and Downgrades: BioNTech, United Airlines, Workhorse and More

Dicerna Pharmaceuticals, Inc. (DRNA) CEO Doug Fambrough on Q2 2021 Results - Earnings Call Transcript

Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -203.92% and -68.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Dicerna Pharmaceuticals (DRNA) Reports Q2 Loss, Misses Revenue Estimates

Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) fell 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 23.26% year over year to ($0.53), which missed the estimate of $0.41.

Dicerna Pharmaceuticals: Q2 Earnings Insights

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today reported its financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Dicerna Announces Second Quarter 2021 Financial Results and Provides a Business Update

A less than satisfying result from a phase 2 trial with nedosiran makes the company's future difficult to predict.

Why Dicerna Pharmaceuticals Stock Is Tumbling on Friday

The stock price of Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) fell by over 25% pre-market. This is why it happened.

DRNA Stock Price Falls Over 25% Pre-Market: Why It Happened

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced positive top-line results from its PHYOX™2 pivotal clinical trial of nedosiran, which is in development for as a treatment for PH.

Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that the Company will release its second quarter 2021 financial results before market open on Monday, Aug. 9, 2021.

Dicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021

Dicerna Pharmaceuticals (DRNA) to Report Q2 Results: Wall Street Expects Earnings Growth

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced the FDA clearance of its IND application for DCR-AUD for the treatment of alcohol use disorder.

Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) has announced interim results from the four completed active-treatment dose cohorts (0.1, 1.0, 3.0, and 6.0 mg/kg) of its Phase 1 trial of belcesiran. The GalXC RNAi therapeutic is in development for alpha-1 antitrypsin deficiency-associated liver disease (AATLD), a rare genetic condition that can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma.

Dicerna Posts Updated Data From Belcesiran Early-Stage Study For Genetic Liver Disease

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced interim results from its Phase 1 trial of belcesiran for treatment of alpha-1 antitrypsin deficiency-associated liver disease.

Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced it has initiated patient dosing in its Phase 2 ESTRELLA trial of belcesiran, which is in development for the treatment of AATLD.

Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease

News for Dicerna Pharmaceuticals Stock (DRNA)